ProCE Banner Activity

RIO: Phase II Study Evaluating bNAbs for HIV Viremia Control

Conference Coverage
Slideset

In placebo-controlled RIO trial in people living with HIV viral suppression, switch to combination of investigational broadly neutralizing antibodies prevented viral rebound during ART interruption.

Released: March 18, 2025

Expiration: September 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare